

ASX Release

Anatara – Board changes

ADELAIDE, 29 September 2025: Anatara Lifesciences Limited (ASX: ANR) ("**Anatara**" or "**the Company**") announces, as part of a Board renewal process, the appointment of Mr Dirk van Dissel to the role of Non-Executive Director effective immediately. In conjunction with the appointment of Dirk van Dissel, Mr Jonathan Lindh will step down from an interim role as Non-Executive Director, while continuing as the Company Secretary.

Anatara's Executive Chair Dr David Brookes commented: "The Company welcomes the experience and knowledge in the biotechnology sector that Dirk van Dissel brings, while being appreciative of Jonathan Lindh's flexibility that assisted us during a hiatus following the GaRP-IBS trial results and the preliminary anti-obesity project preparations required for the proof-of-concept studies. The anti-obesity project is progressing as anticipated and the Company continues to review other opportunities and assets, with some in advanced due diligence."

Mr Dirk van Dissel has more than 20 years' experience in private equity, boutique investment banking and stockbroking. He has provided corporate advisory services and equity capital markets solutions to micro-cap and small-cap companies across the life sciences (biotechnology and healthcare), industrial technology, information and mobile technology, and resources sectors. Mr van Dissel has particular expertise in the identification and evaluation of early-stage healthcare projects, and has extensive experience in capital raising for both ASX-listed and unlisted companies. He has also advised on numerous buy-side and sell-side transactions.

This ASX announcement has been approved and authorised for release by the Board of Anatara.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com

